NSE: APLLTD | BSE: 533573

Mid-range Performer

Download real time

818.30 -10.75 (-1.30%)

28.70% Gain from 52W Low

133.9K NSE+BSE Volume

NSE 02 Jul, 2026 3:31 PM (IST)

16,084.8

Market Cap

High in industry

Beta 1Year

Low volatility

Alembic Pharmaceuticals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for APLLTD, BSE:533573 Alembic Pharmaceuticals Ltd.

Search Inside the pdf :

Alembic Pharmaceuticals Ltd.

19 May 2026

818.30

-1.30%

US Generics Strength, Animal Health Outperformance, and Ex- US Expansion Drive Diversified Growth

Accumulate: Alembic Pharmaceuticals Ltd.

Recommendation Target

Deven Choksey

We expect the company to grow its Revenue/EBITDA/PAT at a CAGR of 10.7% / 20.4% / 20.2% for the period of FY26-FY28E. The company is currently trading at 15x FY28E and we value the company at a PE of 17x FY28E EPS, implying a target price of INR 840 with the upside of 14%.

Number of FII/FPI investors decreased from 195 to 188 in Mar 2026 qtr

Alembic Pharmaceuticals Ltd.

16 May 2026

818.30

-1.30%

Alembic Pharma (BUY): Higher R&D spend underscores focus on US market

Buy: Alembic Pharmaceuticals Ltd.

Target

BOB Capital Markets Ltd.

Sales/EBITDA was reported 4%/24.5% below our estimates; PAT reported 11.9% above our estimates on reporting tax credit

Number of FII/FPI investors decreased from 195 to 188 in Mar 2026 qtr

Alembic Pharmaceuticals Ltd.

05 Feb 2026

818.30

-1.30%

Ex-US and Animal Health perform, while DF and US lag

Neutral: Alembic Pharmaceuticals Ltd.

Target

Motilal Oswal

Alembic Pharma (ALPM) exhibited in-line revenue with a slight miss on EBITDA/PAT for the quarter. While ex-US export growth was strong for the quarter, it was offset by moderate YoY growth in domestic formulation (DF) and US sales.

Alembic Pharma has gained 20.86% in the last 3 Months

Alembic Pharmaceuticals Ltd.

05 Nov 2025

818.30

-1.30%

Strong Q2FY26 performance driven by US generics, margin expansion, and broad-based growth momentum

Buy: Alembic Pharmaceuticals Ltd.

Recommendation Target

Deven Choksey

Alembic Pharma is expected to maintain steady growth momentum supported by its expanding complex generics portfolio in the US, sustained traction in Ex-US markets, and a gradual recovery in the domestic formulations business.

Alembic Pharmaceuticals Ltd. is trading above all available SMAs

Alembic Pharmaceuticals Ltd.

05 Nov 2025

818.30

-1.30%

Export drives the show; India outlook cloudy

Hold: Alembic Pharmaceuticals Ltd.

Target

ICICI Securities Limited

Alembic Pharma’s (Alembic) Q2FY26 result beat our expectations – led by formulations exports (up 25.1% YoY) while India continued to grow at a modest pace (4.9% in Q2FY26).

Alembic Pharma has gained 20.86% in the last 3 Months

Alembic Pharmaceuticals Ltd.

05 Nov 2025

818.30

-1.30%

Alembic Pharma (BUY): All-round beat, US branded product entry to drive margins

Buy: Alembic Pharmaceuticals Ltd.

Target

BOB Capital Markets Ltd.

Sales/EBITDA /PAT reported 7%/4%/8% above our estimates. EBITDA margin was marginally 50 bps below our estimates

Alembic Pharmaceuticals Ltd. is trading above all available SMAs

Alembic Pharmaceuticals Ltd.

05 Nov 2025

818.30

-1.30%

Strong Q2FY26 performance driven by US generics, margin expansion, and broad-based growth momentum

Buy: Alembic Pharmaceuticals Ltd.

Recommendation Target

Deven Choksey

Alembic Pharma has gained 20.86% in the last 3 Months

Alembic Pharmaceuticals Ltd.

12 Aug 2025

818.30

-1.30%

Steady Q1FY26 performance with positive FY26E outlook

Accumulate: Alembic Pharmaceuticals Ltd.

Deven Choksey

We maintain a positive FY26E outlook, expecting sustained double-digit growth across US, Ex-US, and RoW businesses. Growth across regions will be majorly driven by a healthy US pipeline, strategic expansion in RoW, and improved execution across India.

Alembic Pharma has gained 20.86% in the last 3 Months

Alembic Pharmaceuticals Ltd.

06 Aug 2025

818.30

-1.30%

ERRATA: Alembic Pharma (BUY): Strong product mix to drive margins

Buy: Alembic Pharmaceuticals Ltd.

Target

BOB Capital Markets Ltd.

Earnings reported in-line where sales/EBITDA/PAT were -2.6/3.4%/-0.7% above estimates. EBITDA margin was 90 bps above estimates

Number of FII/FPI investors decreased from 195 to 188 in Mar 2026 qtr

Alembic Pharmaceuticals Ltd.

06 Aug 2025

818.30

-1.30%

Turnaround in US growth; tepid traction in India

Hold: Alembic Pharmaceuticals Ltd.

Target

ICICI Securities Limited

Alembic Pharma’s (Alembic) Q1FY26 result was in line with our expectations. Revenue growth was mainly driven by US (13% YoY) and ex-US international business (21% YoY). India growth was tepid at 4.7% YoY due to challenges in specialty portfolio (up 1% YoY) and slowdown in acute market.

Alembic Pharma has gained 20.86% in the last 3 Months

Is Alembic Pharmaceuticals Ltd. worth buying?

246 Votes:

Buy 84.15%

Sell 8.13%

Hold 7.72%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf